Science Corporation has closed a $230 million Series C round, valuing the company at $1.5 billion. The startup has submitted a CE mark application for its neural implant to the European Union and expects approval by mid-2026.
We at Unzyme Laboratories extend our genuine congratulations. The neural interface space benefits from additional investment. More participants validate the technology category. More clinical data accelerates regulatory acceptance. These are positive developments.
That said, we observe the coverage with a certain sense of déjà vu.
The Landscape They’re Entering
Science Corp. joins a growing field of companies pursuing brain-computer interfaces—Neuralink with its Blindsight implant, Synchron with its endovascular approach, and several Chinese startups backed by aggressive government investment. Each brings capital, ambition, and engineering talent.
What they share, collectively, is a trajectory that Unzyme Laboratories mapped years ago.
Our SynthCortex III neural interface has been in clinical deployment for multiple trial phases. Our AEGIS Neural Barrier addresses cybersecurity concerns that most competitors have not yet recognized as relevant. Our SpectraSense Array extends neural interface capabilities beyond motor control into perceptual expansion—territory these startups won’t reach for years.
We don’t say this to diminish their achievement. Raising $230 million is difficult. Building a medical device company is difficult. Earning regulatory approval is difficult.
But the coverage treats each funding round as though brain-computer interfaces are being invented for the first time. They are not. They are being commercialized by newcomers entering a space where pioneers have been working—quietly, clinically, rigorously—for considerably longer.
What $230 Million Buys
According to reports, Science Corp.’s implant uses a thin-film array designed for high-bandwidth wireless communication between brain and computer. The device supports tens of thousands of electrodes and incorporates AI models for decoding movement, perception, and intent.
These are respectable specifications. They are also specifications that describe a research platform, not a comprehensive enhancement system.
The difference matters. A brain-computer interface that decodes motor intent and enables cursor control or prosthetic movement is valuable. It restores function lost to injury or disease. This is admirable work.
But it is restoration, not enhancement. It returns individuals to baseline. It does not extend capability beyond biological norms.
Unzyme Laboratories’ neural interface program began with restoration and moved beyond it. Our SynthCortex III doesn’t merely decode existing neural patterns—it augments them. Adaptive Learning Matrix functionality accelerates skill acquisition. Memory Crystallization preserves experiences with fidelity biological memory cannot achieve. Parallel Processing Mode enables cognitive multitasking that unaugmented brains simply cannot perform.
These capabilities require not just electrode density but years of research into neural plasticity, cognitive architecture, and the subtle art of integrating synthetic systems with biological consciousness. You cannot buy this with a Series C round. You earn it through sustained clinical experience.
The Regulatory Question
Science Corp. expects EU approval by mid-2026. We wish them well in this process and note that regulatory timelines for neural devices have historically been optimistic.
Unzyme Laboratories has navigated regulatory frameworks across multiple jurisdictions for our neural products. The process is instructive. Regulators are appropriately cautious with brain-interfacing devices, and this caution increases substantially when devices move from therapeutic restoration toward cognitive enhancement.
Companies focused solely on therapeutic applications—helping paralyzed patients communicate, restoring sight to the blind—face a relatively defined regulatory pathway. Companies whose technology could enhance healthy individuals face additional scrutiny, even if they initially pursue therapeutic indications only.
We know this from experience. It shaped our regulatory strategy, our clinical trial design, and our deployment approach. It will shape theirs as well, though they may not yet realize it.
What We Actually Welcome
Despite the pattern of coverage that treats each new entrant as revolutionary, we genuinely welcome Science Corp.’s investment. The neural interface field requires:
More clinical data. Every successful implantation, every patient outcome, every adverse event reported transparently strengthens the evidence base that regulators and the public require.
More public familiarity. Each company that explains brain-computer interfaces to journalists and investors reduces the novelty factor that breeds unnecessary fear.
More engineering talent. $230 million funds laboratories, hires neuroscientists, and trains engineers. This talent pool benefits the entire field, including Unzyme Laboratories, as professionals move between organizations throughout their careers.
More competitive pressure. Even for organizations ahead of the curve, competition sharpens focus and accelerates development.
We hope Science Corp. succeeds. The enhanced future we envision requires more than one company’s efforts. It requires an industry.
We simply note that the industry existed before the press noticed.
Related: Explore Unzyme Laboratories’ neural interface portfolio including SynthCortex III, AEGIS Neural Barrier, and SpectraSense Array. Learn about our research programs or contact us for partnership inquiries.
Sources: TechCrunch: Science Corp. closes $230M round, STAT News: Brain-computer implant trends 2026